Simplify Logo

Full-Time

Manager Supply Planning

Posted on 5/2/2024

Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.

501-1,000 employees

Develops therapies for neurological disorders

Consulting
Biotechnology

Compensation Overview

$90k - $112.8kAnnually

+ Bonus + Equity Awards

Senior

San Diego, CA, USA

Category
Supply Chain Management
Operations & Logistics
Required Skills
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Bachelor’s degree in business or science, or related field
  • 5 years of progressively responsible experience in pharmaceutical production and planning
  • Association for Supply Chain Management (ASCM or APICS) certification preferred
  • Strong knowledge of ERP software systems and procedures
  • Experience with maintaining adequate stocks of drug product, active pharmaceutical ingredients (API), and key raw materials
  • Experience with cold chain products and subsequent supply chain
  • In-depth knowledge of GMP principles
  • Proficient in Excel and PowerPoint
  • Experience engaging in CMO contract relationships and planning
  • Ability to travel 10% of the time both domestically and internationally
Responsibilities
  • Ensure no stock-outs of Acadia commercial products
  • Issue, track, and maintain Purchase Orders (PO's) to Contract Manufacturing Organizations (CMO’s)
  • Perform receipts and any required inventory transactions in ERP systems
  • Oversee product planning (PP) systems and activities
  • Develop and produce planning metrics for management review
  • Assess supply chain robustness through scenario analysis activities
  • Coordinate with Finance in managing cost of goods
  • Identify, communicate, and elevate supply chain problems
  • Drive and optimize processes and procedures to support growth and complexity of Acadia supply planning
Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. Their products are created through extensive research and development, followed by rigorous clinical trials to ensure safety and effectiveness. Once approved by regulatory bodies like the FDA, these therapies are marketed to patients and healthcare providers. Acadia stands out from competitors by concentrating on areas with significant unmet medical needs and fostering strategic partnerships to enhance their research and market presence. The company's goal is to improve the quality of life for individuals with neurological conditions through effective treatments.

Company Stage

IPO

Total Funding

$813.4M

Headquarters

Dallas, Texas

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's launch of Magnolia's Guide to Adventuring showcases their innovative approach to raising disease awareness and redefining perceptions of Rett syndrome.
  • The acceptance of trofinetide for priority review by Health Canada could lead to significant market expansion and first-mover advantage in treating Rett syndrome in Canada.
  • The appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development, signals a strong commitment to advancing their R&D capabilities.

What critics are saying

  • The failure of the Phase III ADVANCE-2 trial for pimavanserin in schizophrenia highlights the high-risk nature of drug development in the biopharmaceutical sector.
  • Dependence on regulatory approvals, such as the FDA and Health Canada, introduces uncertainty and potential delays in bringing therapies to market.

What makes Acadia Pharmaceuticals Inc. unique

  • Acadia Pharmaceuticals focuses exclusively on neurological disorders, setting it apart from competitors with broader therapeutic areas.
  • Their commitment to corporate social responsibility, including initiatives like the Rett Sibling Scholarship, enhances their reputation and community engagement.
  • Acadia's strategic partnerships and corporate sponsorships amplify their research capabilities and market reach, distinguishing them from competitors who may not leverage such collaborations.
INACTIVE